51.67 0.00 (0.00%)
After hours: 5:51PM EST
|Bid||51.70 x 800|
|Ask||51.76 x 1800|
|Day's Range||50.92 - 51.87|
|52 Week Range||44.30 - 70.05|
|Beta (3Y Monthly)||0.84|
|PE Ratio (TTM)||17.05|
|Earnings Date||Apr 24, 2019 - Apr 29, 2019|
|Forward Dividend & Yield||1.64 (3.23%)|
|1y Target Est||56.58|
Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Bristol-Myers Squibb Company and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers. This publication does not announce a credit rating action and is not an indication of whether or not a credit rating action is likely in the near future.
Nektar Therapeutics said on Friday some patients with advanced bladder cancer treated with a combination of its experimental treatment and Bristol-Myers Squibb Co's immunotherapy, Opdivo, showed signs of tumor reduction in an early-stage study. Of the 27 patients with urothelial cancer, 19 percent showed complete response after being treated with the combo therapy using Nektar's NKTR-214, according to data, which was presented at the Genitourinary Cancers Symposium in San Francisco. The disease, which can infect any part of the urinary tract including the renal pelvis and the bladder, is the sixth most common type of cancer in the United States, the company said.
U.S. stock futures are flat this morning but well off the overnight dips. In early morning trading, the futures on the Dow Jones Industrial Average are up 0.38% and S&P 500 futures are higher by 0.41%. Nasdaq-100 futures have added 0.49%.In the options pits, call buyers were still the busier bunch on Thursday, but the markets had a tizzy brought by the weakest retail sales report since 2009. We also had news that things are not going well with the China tariff deal. Now we are in a stalemate while we await the next meeting or headline. Wall Street is waiting for confirmation before they eliminate the risks from those fronts. The action was more cautious than Wednesday. We saw the options balance shift slightly more bearish, with only 18.1 million calls and 16.3 million puts during the session.However, there is still overall caution among many skeptics of this rally. The CBOE single-session equity put/call volume ratio inched up to 0.6. This is now almost at the 10-day moving average of 0.61.InvestorPlace - Stock Market News, Stock Advice & Trading TipsAlthough options activity was cautious on Thursday, there were a few standouts in options trading. Bristol-Myers Squibb (NYSE:BMY), Activision Blizzard (NASDAQ:ATVI) and Intel (NASDAQ:INTC) had unusual levels of options activity or an unusual mix. This typical is a precursor to sizable stock moves.Let's take a closer look: Bristol-Myers (BMY)BMY stock has seen better days. Last year started well for it, but after topping out in the middle of February, it went into a 35% correction from top to bottom. 2019 started even worse when the stock fell to a new low of $44.30 on Jan. 3 when they announced the Celgene (NASDAQ:CELG) buyout. * 10 Hot Stocks Leading the Market's Blitz Higher Since then, Bristol Meyers stock has rallied and now showing some appetite to continue even further. Options traders on Thursday traded 214% of its daily average. They were still split almost evenly between calls and puts but it does show their interest in it.This is an indication that there should be a move -- most likely the continuation of the current trend. Buying calls is a cheap way to bet on the upside. Conversely, buying puts is a cheap way to buy temporary protection while remaining long the stock. Here they are both active, so investors are still engaged.If the bulls can breakout through $51.50 area then they would have the opportunity to retest $52.90. If that happens, it would offer yet another upside breakout line. So what is happening here is that investors are using options to ride out this mini rally so they can get to bigger rewards above.This is a quality, healthy company whose stock is temporarily broken … but the company is not. The market eventually will fix this so that the trend reflects the actual company prospects. Activision Blizzard (ATVI)The worst may be over for Activision stock, at least for now. This stock, along with many in the sector, have been under severe pressure from major shifts in their customer trends. But it seems like ATVI is adjusting and managing their businesses to right the ship.I recently wrote an article on how to trade the short-term ATVI. In it I noted the breakout potential from $44.30 to $45.60. This upside potential has almost filled as of yesterday but there still is potential upside even above it.The ATVI zone around the recent high of $46.58 per share will now serve as the next breakout potential to target $48 per share and fill the entire Feb. 5 gap. It will need the general market's help and it may take a few days to do it. Eventually, this creep higher will break the long-term descending trend line of lower highs and a much bigger breakout will ensue.This is a long way of saying that the Activision stock has probably bottomed and that it will have a chance at recovering all the way back to $56 per share. There are areas of resistance at several spots along the way, the most major of which are at $49.50, $51.6o and $$53 per share. Intel (INTC)Intel stock mounted a respectable 14% rally off the December lows. The day it went into the earnings event, INTC stock was on the verge of a secondary breakout line. Unfortunately, Wall Street did not like the earnings report headline and the stock sold off as much as 8% when it opened.But this was a fake-out bear trap because since then, the stock has risen 10%. Now it is once more at the verge of another chance at that breakout. The measured move from that would target $56 per share. There will be resistance at $53.20 and $54.70.Now that the gap is almost closed, I weigh the odds of it being the target of this ongoing rally against the idea that this is a mega breakout with $56 per share as the eventual target.I was a bit disappointed that they gave the interim CEO the job for good, especially after such a long search period. But since then, investors have accepted the decision so it's no longer an overhanging issue and my feeling don't matter to how I trade it.Nicolas Chahine is the managing director of SellSpreads.com. As of this writing, he did not hold a position in any of the aforementioned securities. You can follow him as @racernic on Twitter and Stocktwits. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The 10 Best ETFs You Can Buy * 7 Reasons Stock Buybacks Should Be Illegal * Should You Buy, Sell, Or Hold These 7 Medical Cannabis Stocks? Compare Brokers The post Fridayas Vital Data: Bristol-Myers Squibb, Intel and Activision Blizzard appeared first on InvestorPlace.
First I-O/I-O combination regimen to demonstrate response rates in this hard-to-treat patient population
Johnson & Johnson (JNJ) entered into a definitive agreement to acquire Auris Health, Inc., a developer of robotic technologies focused on lung cancer, for approximately $3.4 billion in cash.
Shares of Viking Therapeutics (NASDAQ:VKTX) are making headlines this week after an announcement from Gilead Sciences (NASDAQ:GILD), that one of its drugs did not meet the primary endpoints of its Phase 3 clinical trial. This gave a possible opening to Viking Therapeutics, which gave a boost to VKTX stock.Source: Shutterstock Does that make it a buy? Let's examine the stock a bit more closely. If you haven't heard of VKTX stock before, don't feel guilty. With a market cap of just $650 million, it's not a well-known company. It's not a Bristol-Myers Squibb (NYSE:BMY), Celgene (NASDAQ:CELG), Biogen (NASDAQ:BIIB) or another large cap biotech company. Breaking Down VKTX StockViking Therapeutics is a self-described "clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders." The company is working on several treatments, one of which includes enrolling VK2809, which is aimed at fatty liver and hypercholesterolemia, in a Phase 2 study. Gilead's Selonsertib liver treatment failed its Phase 3 clinical trial earlier this week, thus giving some hope to VKTX stock.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 9 U.S. Stocks That Are Coming to Life Again The company also has VK5211, "an orally available, non-steroidal SARM designed to selectively stimulate muscle and bone formation."At the end of the day, Viking Therapeutics has some intriguing developments in its pipeline. But at the same time, this is also a speculative biotech company. Investors are, to some degree, betting on a binary event. Either VKTX stock is a multi-bagger with big-time potential if it gains regulatory approval and/or is acquired by a larger company, or neither of those things happen and it's a total dud. That's the nature of the beast with young biotech stocks.Case in point? Viking Therapeutics stock doesn't have any revenue. Its pipeline is promising, but that's all investors are betting on at this point. There's no real way to evaluate the business because there is no business! At least in the traditional sense. VKTX has enough money in the bank to fund its operations for the time being, but its future hinges solely on its treatments. Trading VKTX StockHopefully the chart above doesn't seem too complex. I only wanted to lay out a few different levels and prior trends that played a role in VKTX stock over the last 12 months.Like most of the market, VKTX came into Q4 near its highs, although admittedly under some pressure already. Still, the stock was pummeled along with the S&P 500 and other major market indices as Q4 got under way. VKTX stock price bottomed near $7 on Christmas Eve and has been working higher since.VKTX stock is now over the 50-day and 21-day moving averages. For traders and investors that are going in on this, perhaps consider using a $7 as a key reference level. Below this mark and Viking Therapeutics stock could be in trouble.As much as I want to say that the stock is okay over uptrend support (purple line) and moving average support -- and really, it is -- know that this is a speculative position that is subject to extreme moves in both directions. These moves can appear overnight and there's little investors can do about it other than planning ahead with proper position sizing. * Should You Buy, Sell, Or Hold These 7 Medical Cannabis Stocks? For those that don't want such a speculative position, consider choosing between two companies like Celgene and Gilead.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell is long CELG. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 9 U.S. Stocks That Are Coming to Life Again * The 7 Best Video Game Stocks to Power Up Your Portfolio! * 5 Tips to Become a Better Stock Trader Compare Brokers The post Should You Buy Viking Therapeutics After Gilead Drug Failure? appeared first on InvestorPlace.
AstraZeneca (AZN) beats earnings and sales estimates in the fourth quarter and provides encouraging outlook for 2019. Shares up.
Aethlon (AEMD) reported financial results for their fiscal third quarter ending December 31st and provided a business update. While we had modeled an initial payment under their ongoing NCI grant (The Hemopurifier Device for Targeted Removal of Breast Cancer Exosomes from the Blood Circulation), which was awarded in September and will pay a total of $298.4k through ~August 2019, initial revenue is now expected to be recognized in the current (i.e.
When Gilead Sciences (NASDAQ:GILD) reported earnings earlier this month, shares stagnated a bit but stayed above the 50-day moving average. That gave investors a reasonable level to measure against. However, Gilead stock is lower on Tuesday following disappointing drug data.Specifically, Gilead's selonsertib drug failed its phase 3 clinical trial. Even though GILD stock is off the lows, that's causing selling pressure on Tuesday and brings up a more broad question: Which stock is better, Gilead or Celgene (NASDAQ:CELG)? * The 7 Best Video Game Stocks to Power Up Your Portfolio! I believe the latter offers a better value right now, despite the fact that Bristol-Myers Squibb (NYSE:BMY) has already announced that it will buy Celgene. Let's look at both stocks more closely.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Sizing Up Gilead StockWhen Gilead reported fourth-quarter earnings, it missed analysts' earnings expectations of $1.69 per share by 25 cents and reported a 2.5% decline in sales. For 2019, analysts are currently forecasting a 30 basis point decline in sales, following a more than 15% decline in 2018. Further, they expect roughly flat earnings growth from last year's non-GAAP earnings of $6.67 per share.That's not all that great, but considering the stock trades at roughly 10 times this year earnings, at least aren't paying an egregious valuation. Further, at least the year-over-year declines are abating, unlike 2018's haircut.In other words, while Gilead doesn't have an attractive growth profile, it's likely put the worst behind it and is looking at moving forward. Plus, the stock yields about 3.75%, not bad in most investors' eyes. The company has $31.5 billion in cash and roughly the same amount in long-term debt. Finally, while Gilead stock still kicks off a solid amount of free-cash flow, it's been under notable pressure over the past few years. Why Celgene Stock Looks Better To be fair, it's not a simple argument that Gilead stock is trash and Celgene is great. In fact, Celgene has its own issues too, but it helps that BMY is there with a bid. It also helps that Celgene has growth.Analysts expect Celgene to grow sales 11.7% this year and 12.8% in 2020. On the earnings front, consensus expectations call for 18.7% growth in both years. That's pretty impressive when you think it, particularly when you consider that CELG stock trades at 8.5 times this year's earnings estimate.While Celgene may not pay a dividend like Gilead stock, shares are cheaper and have far better growth. Free cash flow is trending higher (not lower) as well. Now for the buyout.Bristol-Myers will pay $50 per share in cash, plus give one share of BMY for each share of CELG. At current prices, that values CELG at about $100 per share. Celgene also receives a $2 billion breakup fee if the deal falls through and shareholders could receive an additional $9 per share should three of Celgene's treatments achieve various milestones. * 9 U.S. Stocks That Are Coming to Life Again Assuming the deal goes through, let's also not forget that converting to BMY stock wouldn't be the worst thing the world. Either way, with CELG still trading at a discount to the takeover price, investors are getting a good deal. The big downside is if the deal doesn't go through. That's a risk that doesn't come with Gilead stock and should that happen, CELG shares will likely plunge in response.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell is long CELG. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The 7 Best Video Game Stocks to Power Up Your Portfolio! * 7 Forever Stocks to Buy for Long-Term Gains * 5 Self-Driving Car Stocks to Buy Compare Brokers The post Celgene vs. Gilead Stock: What's the Better Biotech Buy? appeared first on InvestorPlace.
Pfizer (PFE)/Merck KGaA's label expansion application for Bavencio as a treatment for advanced kidney cancer in combination with Inlyta gets priority review in the United States. The decision is expected in June.
J&J (JNJ) gets FDA advisory committee's positive recommendation for its investigational nasal spray, Spravato (esketamine) for treatment-resistant depression in adults.
The Zacks Analyst Blog Highlights: Bristol-Myers, ConocoPhillips, Qualcomm, General Motors and Marathon
AbbVie (ABBV) enters a global strategic transaction agreement with privately-held Teneobio to develop and commercialize the latter's pre-clinical immunotherapy candidate, TNB-383B, as a multiple myeloma treatment.
Aduro (ADRO) doses the first patient in a phase I study on ADU-S100 in combination with Yervoy for the treatment of relapsed and refractory melanoma. Shares rise.
Bristol-Myers' (BMY) oncology drug, Sprycel in combination with chemotherapy gets EC approval to treat pediatric patients with newly diagnosed Ph+ ALL.
Seattle Genetics' (SGEN) partner, Takeda Pharmaceutical receives EC approval for Adcetris in combination with AVD to treat adults with previously untreated CD30+ stage IV cHL.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 11) Boston Scientific Corporation (NYSE: BSX ) Inspire ...